PARP Inhibition in the Treatment of Pancreatic Cancer: Current and Future Perspectives on Personalized Therapy

Results from NAPOLI 3 trial of first-line NALIRIFOX vs gemcitabine + nab-paclitaxel in mPDAC, presented at ASCO GI 2023 as reported by Clinical Care Options (CCO)

In slides from Clinical Care Options (CCO), experts provide perspectives on updates in biomarker testing and targeted therapy across GI cancers

John L. Marshall, MD
Program Director Christopher H. Lieu, MD Manish A. Shah, MD Released: January 19, 2023

Experts highlight key studies being presented at the upcoming 2023 ASCO GI annual meeting in this commentary from Clinical Care Options (CCO)

Christopher H. Lieu, MD Rachna Shroff, MD, MS Released: January 19, 2023

Expert review of key data in GI cancers from the 2022 ASCO Annual Meeting, from Clinical Care Options (CCO)

Christopher H. Lieu, MD Rachna Shroff, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: August 31, 2022 Expired: August 30, 2023